A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Status:
Recruiting
Trial end date:
2025-03-04
Target enrollment:
Participant gender:
Summary
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study
assessing the efficacy and safety of durvalumab compared with placebo, as consolidation
therapy in patients with locally advanced, unresectable, non-small cell lung cancer (Stage
III), who have not progressed following definitive, platinum-based, chemoradiation therapy.